Regeneron Pharmaceuticals Stock Buy Hold or Sell Recommendation
| REGN Stock | USD 681.58 11.65 1.68% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Regeneron Pharmaceuticals is 'Hold'. The recommendation algorithm takes into account all of Regeneron Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
Check out Regeneron Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide. In addition, we conduct extensive research on individual companies such as Regeneron and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Regeneron |
Execute Regeneron Pharmaceuticals Buy or Sell Advice
The Regeneron recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Regeneron Pharmaceuticals. Macroaxis does not own or have any residual interests in Regeneron Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Regeneron Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Regeneron Pharmaceuticals Trading Alerts and Improvement Suggestions
| Regeneron Pharmaceuticals generated a negative expected return over the last 90 days | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from statnews.com: The most essential and memorable JPM moments, recapped |
Regeneron Pharmaceuticals Returns Distribution Density
The distribution of Regeneron Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Regeneron Pharmaceuticals' future price movements. The chart of the probability distribution of Regeneron Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Regeneron Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Regeneron Pharmaceuticals returns is essential to provide solid investment advice for Regeneron Pharmaceuticals.
| Mean Return | -0.56 | Value At Risk | -3.63 | Potential Upside | 1.89 | Standard Deviation | 1.90 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Regeneron Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Regeneron Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Regeneron Pharmaceuticals, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Regeneron Pharmaceuticals back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.2 M | Loomis, Sayles & Company Lp | 2024-09-30 | 1.2 M | Amvescap Plc. | 2024-09-30 | 1.2 M | Norges Bank | 2024-06-30 | 1.1 M | Amundi | 2024-09-30 | 1.1 M | Bank Of America Corp | 2024-09-30 | 993.2 K | Legal & General Group Plc | 2024-09-30 | 959.1 K | Northern Trust Corp | 2024-09-30 | 918.6 K | International Assets Investment Management, Llc | 2024-09-30 | 880.9 K | Fmr Inc | 2024-09-30 | 10.4 M | Vanguard Group Inc | 2024-09-30 | 9.3 M |
Regeneron Pharmaceuticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 577M | 690.8M | 221.3M | (381.6M) | (438.8M) | (416.9M) | |
| Free Cash Flow | 2.0B | 6.5B | 4.4B | 3.7B | 4.2B | 4.4B | |
| Depreciation | 235.9M | 286.2M | 341.4M | 421M | 484.2M | 508.4M | |
| Other Non Cash Items | (135M) | 181.7M | 599.8M | 266.3M | 306.2M | 321.6M | |
| Capital Expenditures | 614.6M | 551.9M | 590.1M | 926.4M | 1.1B | 1.1B | |
| Net Income | 3.5B | 8.1B | 4.3B | 4.0B | 4.5B | 4.8B | |
| End Period Cash Flow | 2.2B | 2.9B | 3.1B | 2.7B | 3.1B | 3.3B | |
| Change To Inventory | (529.4M) | (494.3M) | (696.5M) | (271.7M) | (244.5M) | (232.3M) | |
| Investments | 544M | (4.8B) | (1.9B) | (5.0B) | (4.5B) | (4.3B) | |
| Change To Netincome | 314.2M | (895.1M) | (994M) | 676.5M | 608.9M | 639.3M |
Regeneron Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Regeneron Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Regeneron Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Regeneron stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.57 | |
β | Beta against Dow Jones | 0.13 | |
σ | Overall volatility | 1.96 | |
Ir | Information ratio | -0.3 |
Regeneron Pharmaceuticals Volatility Alert
Regeneron Pharmaceuticals exhibits very low volatility with skewness of -1.64 and kurtosis of 5.67. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Regeneron Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Regeneron Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Regeneron Pharmaceuticals Fundamentals Vs Peers
Comparing Regeneron Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Regeneron Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Regeneron Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Regeneron Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Regeneron Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Regeneron Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Regeneron Pharmaceuticals to competition |
| Fundamentals | Regeneron Pharmaceuticals | Peer Average |
| Return On Equity | 0.17 | -0.31 |
| Return On Asset | 0.0741 | -0.14 |
| Profit Margin | 0.34 % | (1.27) % |
| Operating Margin | 0.33 % | (5.51) % |
| Current Valuation | 70.21 B | 16.62 B |
| Shares Outstanding | 108.07 M | 571.82 M |
| Shares Owned By Insiders | 1.57 % | 10.09 % |
| Shares Owned By Institutions | 90.64 % | 39.21 % |
| Number Of Shares Shorted | 2.1 M | 4.71 M |
| Price To Earning | 15.51 X | 28.72 X |
| Price To Book | 2.64 X | 9.51 X |
| Price To Sales | 5.50 X | 11.42 X |
| Revenue | 13.12 B | 9.43 B |
| Gross Profit | 7.03 B | 27.38 B |
| EBITDA | 4.05 B | 3.9 B |
| Net Income | 3.95 B | 570.98 M |
| Cash And Equivalents | 7.02 B | 2.7 B |
| Cash Per Share | 65.75 X | 5.01 X |
| Total Debt | 2.7 B | 5.32 B |
| Debt To Equity | 0.13 % | 48.70 % |
| Current Ratio | 5.36 X | 2.16 X |
| Book Value Per Share | 272.04 X | 1.93 K |
| Cash Flow From Operations | 4.59 B | 971.22 M |
| Short Ratio | 2.44 X | 4.00 X |
| Earnings Per Share | 40.45 X | 3.12 X |
| Price To Earnings To Growth | 1.04 X | 4.89 X |
| Target Price | 1005.65 | |
| Number Of Employees | 14.16 K | 18.84 K |
| Beta | 0.14 | -0.15 |
| Market Capitalization | 76.18 B | 19.03 B |
| Total Asset | 33.08 B | 29.47 B |
| Retained Earnings | 27.26 B | 9.33 B |
| Working Capital | 16.06 B | 1.48 B |
Note: Acquisition by Joseph LaRosa of 2332 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 [view details]
Regeneron Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Regeneron . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 41243.14 | |||
| Daily Balance Of Power | (0.44) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 694.31 | |||
| Day Typical Price | 690.06 | |||
| Price Action Indicator | (18.55) | |||
| Period Momentum Indicator | (11.65) |
About Regeneron Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Regeneron Pharmaceuticals? Buying financial instruments such as Regeneron Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Regeneron Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Obamacare Repeal Thematic Idea Now
Obamacare Repeal
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Regeneron Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.298 | Earnings Share 40.45 | Revenue Per Share | Quarterly Revenue Growth 0.106 | Return On Assets |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.